Evidence map›Paper›PMID 33814447›Full record

Trial reportJournal of Alzheimer's disease : JAD2021

A Precision Medicine Approach to Treating Alzheimer's Disease Using Rosiglitazone Therapy: A Biomarker Analysis of the REFLECT Trials.

Sid E O'Bryant, Fan Zhang, Melissa Petersen, Leigh Johnson, James Hall, Robert A Rissman

Open access · bronzeAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of Alzheimer's disease : JAD, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Precision medicine for Alzheimer's disease in Down syndrome.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Fountain of youth-Targeting autophagy in aging.Frontiers in aging neuroscience · 2023
    Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Sid E O'BryantInstitute for Translational Research, University of North Texas Health Science Center, Fort Worth, TX, USA.
Fan ZhangInstitute for Translational Research, University of North Texas Health Science Center, Fort Worth, TX, USA.
Melissa PetersenInstitute for Translational Research, University of North Texas Health Science Center, Fort Worth, TX, USA.
Leigh JohnsonInstitute for Translational Research, University of North Texas Health Science Center, Fort Worth, TX, USA.
James HallInstitute for Translational Research, University of North Texas Health Science Center, Fort Worth, TX, USA.
Robert A RissmanDepartment of Family Medicine, University of North Texas Health Science Center, Fort Worth, TX, USA.
University of North Texas · US

Funding

UCSD Shiley-Marcos Alzheimer's Disease Research Center P30P30AG062429 · UNIVERSITY OF CALIFORNIA, SAN DIEGO · 2025 to 2025
$4.6M
B-Synuclein as a Treatment for Lewy Body DiseaseR01AG018440 · UNIVERSITY OF CALIFORNIA SAN DIEGO · 2001 to 2005
$1.6M
NIA NIH HHS P30 AG062429NIA NIH HHS R01 AG018440NIA NIH HHS R01 AG051848
6 · The paper itself

Abstract

backgroundThe REFLECT trials were conducted to examine the treatment of mild-to-moderate Alzheimer's disease utilizing a peroxisome proliferator-activated receptor gamma agonist.

objectiveTo generate a predictive biomarker indicative of positive treatment response using samples from the previously conducted REFLECT trials.

methodsData were analyzed on 360 participants spanning multiple negative REFLECT trials, which included treatment with rosiglitazone and rosiglitazone XR. Support vector machine analyses were conducted to generate a predictive biomarker profile.

resultsA pre-defined 6-protein predictive biomarker (IL6, IL10, CRP, TNFα, FABP-3, and PPY) correctly classified treatment response with 100%accuracy across study arms for REFLECT Phase II trial (AVA100193) and multiple Phase III trials (AVA105640, AV102672, and AVA102670). When the data was combined across all rosiglitazone trial arms, a global RSG-predictive biomarker with the same 6-protein predictive biomarker was able to accurately classify 98%of treatment responders.

conclusionA predictive biomarker comprising of metabolic and inflammatory markers was highly accurate in identifying those patients most likely to experience positive treatment response across the REFLECT trials. This study provides additional proof-of-concept that a predictive biomarker can be utilized to help with screening and predicting treatment response, which holds tremendous benefit for clinical trials.

Indexed as

Precision MedicineAlzheimer DiseaseHumansHypoglycemic AgentsPPAR gammaRosiglitazoneThiazolidinedionesHypoglycemic AgentsPPAR gammaRosiglitazoneThiazolidinedionesAlzheimer’s diseaseclinical trialpredictive biomarkerrosiglitazone

Identifiers

PMID33814447
PMCPMC8203239
OpenAlexW3151295712

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.